Noah Goodman Sells 2,500 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Posted by George Bondi on Jun 24th, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) insider Noah Goodman sold 2,500 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $99.00, for a total transaction of $247,500.00. Following the completion of the sale, the insider owned 50,195 shares of the company’s stock, valued at approximately $4,969,305. The trade was a 4.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Noah Goodman also recently made the following trade(s):

On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.00, for a total value of $121,230.00.
On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total value of $174,700.00.
On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total value of $723,100.00.

Kymera Therapeutics Stock Down 1.2%

NASDAQ KYMR opened at $98.25 on Wednesday. Kymera Therapeutics, Inc. has a 52 week low of $36.65 and a 52 week high of $105.00. The business’s fifty day simple moving average is $83.67 and its 200-day simple moving average is $81.54. The firm has a market cap of $8.08 billion, a PE ratio of -27.52 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. During the same quarter in the prior year, the firm posted ($0.82) earnings per share. Kymera Therapeutics’s quarterly revenue was up 55.5% on a year-over-year basis. Research analysts expect that Kymera Therapeutics, Inc. will post -3.25 EPS for the current year.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after purchasing an additional 1,833 shares in the last quarter. Millennium Management LLC lifted its holdings in Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after buying an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after buying an additional 491,737 shares during the period. Invesco Ltd. boosted its position in Kymera Therapeutics by 13.8% in the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock valued at $2,090,000 after buying an additional 5,809 shares during the period. Finally, Sei Investments Co. acquired a new position in shares of Kymera Therapeutics in the second quarter worth $265,000.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

Positive Sentiment: Kymera’s last reported quarter beat expectations, with EPS of ($0.71) versus the ($0.89) consensus and revenue of $34.37 million versus $8.27 million, reinforcing confidence in the business outlook.
Positive Sentiment: A Zacks note said KYMR shares surged in the prior session on above-average volume, with recent earnings-estimate revisions suggesting there may be additional upside near term. Article Title
Neutral Sentiment: Several insider transactions were disclosed under pre-arranged Rule 10b5-1 plans, which often makes them less concerning as a signal about near-term fundamentals.
Negative Sentiment: Director Bruce Booth sold multiple large blocks of shares, including a $24.3 million sale and additional recent sales, and insider Noah Goodman also sold shares. While these were planned transactions, the volume and frequency can weigh on sentiment. Article Title

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Canaccord Genuity Group initiated coverage on Kymera Therapeutics in a research report on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price objective for the company. Stephens upped their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Citigroup raised their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 8th. Finally, Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $117.14.

Read Our Latest Report on Kymera Therapeutics

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.